Drug discovery

#Biomarkers #Drug discovery #Evotec #Immunoassays #Webinar

Webinar unpacks immunoassays for clinical biomarkers

When biomarkers are present at very low concentrations, conventional immunoassays may not provide the sensitivity needed to generate reliable, meaningful data. This can limit the ability to assess target engagement, monitor pharmacodynamic responses and track biomarker changes during treatment. Ultrasensitive immunoassays offer new opportunities to address these challenges. In this… Read More

#News

#DDII #DDIIDigitalForum #Drug discovery

This week in Drug Discovery (9-13 November)

News round-up for 9-13 November 2026 by Diana Turner, Deputy Editor at DDW.  From pharma and AI collaborations to financing deals that will enable expansion, this week’s news roundup focuses on the theme of partnership, a key factor in success in the drug discovery and development industry. Read More

#News

#Artificial intelligence (AI) #Automation / robotics #Collaboration #Drug discovery #Pierre Fabre #XtalPi

Pierre Fabre and XtalPi team up on drug discovery

Pharmaceutical company Laboratoires Pierre Fabre and AI platform company XtalPi have announced a collaboration to discover novel drug candidates across oncology, rare diseases, and dermatology.  Under the agreement, XtalPi will use its integrated AI capabilities and robotics platform to de novo design and deliver novel small molecule… Read More

#Business & Investment #News

#Biomarkers #Drug discovery #Evotec #Immunoassays #Webinar

Register for insight on ultrasensitive immunoassays for clinical biomarkers

When biomarkers are present at very low concentrations, conventional immunoassays may not provide the sensitivity needed to generate reliable, meaningful data. This can limit the ability to assess target engagement, monitor pharmacodynamic responses and track biomarker changes during treatment. Ultrasensitive immunoassays offer new opportunities to address these challenges. In this… Read More

#News

Examining a sample under the microscope
#Crown Bioscience #Drug discovery #PDX models #Webinar

Webinar goes beyond the model to explore warm PDX benefits and onsite expertise

Patient-derived xenograft (PDX) models are a valuable tool in oncology research, helping researchers evaluate therapeutic efficacy in preclinical settings using models that retain key characteristics of human tumours. In this webinar, Crown Bioscience will highlight the capabilities of its PDX model portfolio, with a particular focus on the benefits of… Read More

#News

#Benchling #Biology #Chemistry #Drug discovery #Webinar

Webinar: Connecting chemistry and biology for smarter drug discovery

A molecule passes through many hands in drug discovery. Medicinal chemists design and synthesise it, analytical scientists characterise it, and biology teams evaluate its activity. Yet the scientific knowledge generated along the way often remains fragmented across disconnected systems, making it difficult to connect what was made, how it was… Read More

#News

#Biomarkers #Drug discovery #Evotec #Webinar

Last chance to register: Webinar unpacks PK/PD and QSP modeling

Clinical trials continue to experience high attrition rates, with lack of efficacy being one of the leading causes of failure. However, in many cases, these failures do not reflect a lack of drug efficacy, but rather limitations in translational biomarker strategies and selection of disease-relevant pharmacodynamic (PD) biomarkers, suboptimal dose… Read More

#News

#Artificial intelligence (AI) #Automation #Benchling #Drug discovery #Webinar

North America Session – From reaction to result: Connecting chemistry and biology for smarter drug discovery

A molecule passes through many hands in drug discovery. Medicinal chemists design and synthesise it, analytical scientists characterise it, and biology teams evaluate its activity. Yet the scientific knowledge generated along the way often remains fragmented across disconnected systems, making it difficult to connect what was made, how it was… Read More

Webinar date:
Supported by Benchling
#Featured Webinars #Webinars

#Artificial intelligence (AI) #Automation #Benchling #Drug discovery #Webinar

Europe Session – From reaction to result: Connecting chemistry and biology for smarter drug discovery

A molecule passes through many hands in drug discovery. Medicinal chemists design and synthesise it, analytical scientists characterise it, and biology teams evaluate its activity. Yet the scientific knowledge generated along the way often remains fragmented across disconnected systems, making it difficult to connect what was made, how it was… Read More

Webinar date:
Supported by Benchling
#Featured Webinars #Webinars

Fluorescent Immunohistochemistry
#Assays #Cell Science #Drug discovery #Drug targets #Immunohistochemistry

Find validated IHC and mIF markers for your target before your study starts

This new free download can help researchers avoid assay development delays. Download this reference list from Crown Bioscience, which shows what is already validated and ready to run. You will learn: 500+ Human IHC markers for RUO, IVD or CDx Prevalidated 5 to 7-color mIF panels suitable for IO and… Read More

#News

#DDII #DDIIDigitalForum #Drug discovery

This week in Drug Discovery (2-6 November)

News round-up for 2-6 November 2026 by Diana Turner, Deputy Editor at DDW.  Following the success of the Drug Discovery Innovators and Investors (DDII) London event, which brought together representatives from across the UK life sciences sector, this week’s round-up centres on stories that highlight the importance of… Read More

#News

#DDII #DDIIeventseries #DDIIUK2026 #Drug development #Drug discovery #Events

Drug Discovery Innovators and Investors (DDII) conference: Event summary

The second event in the Drug Discovery Innovators and Investors (DDII) event series took place on 4 November, 2026, bringing together representatives from across the UK life sciences sector to discuss the opportunities and challenges facing drug discovery and development. Held in London under the theme Technology, Scale, and Capital:… Read More

#News

#Crown Bioscience #Drug discovery #PDX models #Webinar

Register to learn about warm PDX benefits and onsite expertise

Patient-derived xenograft (PDX) models are a valuable tool in oncology research, helping researchers evaluate therapeutic efficacy in preclinical settings using models that retain key characteristics of human tumours. In this webinar, Crown Bioscience will highlight the capabilities of its PDX model portfolio, with a particular focus on the benefits of… Read More

#News